10-K: VitaNova Life Sciences Reports FY26 Results, Revenue Up 14%

VitaNova Life Sciences Corporation's annual report for fiscal year 2026 shows a 14% increase in revenue to $3.03 million, driven by its new healthy food products line, though net income turned to a loss of $37,304.

Summary

• VitaNova Life Sciences Corporation reported revenues of $3,025,538 for the fiscal year ended April 30, 2026, a 14% increase from $2,662,105 in the prior year, primarily due to growth in its healthy food products line.
• The company experienced a net loss of $37,304 for FY2026, a significant shift from a net income of $850,746 in FY2025.
• Gross profit margin decreased from 59% in FY2025 to 30% in FY2026, largely attributed to the lower profit margin of the new food products and a decrease in higher-margin dietary supplement sales.
• Operating expenses increased substantially by 146% to $906,988 in FY2026, mainly due to higher legal and professional fees, and increased stock compensation expense.
• The company's cash position improved significantly, ending FY2026 with $1,597,217 in cash, up from $782,810 at the end of FY2025.
• Disclosure controls and internal financial reporting controls were found to be not effective, with material weaknesses identified related to the lack of an independent audit committee and insufficient qualified accounting personnel.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant decline in profitability and the shift from net income to a net loss, despite revenue growth. The increase in operating expenses and the decrease in gross margin are key concerns.

Positives

• Revenue increased by 14% to $3,025,538 in FY2026, driven by the new healthy food products line.
• Cash and cash equivalents increased to $1,597,217 as of April 30, 2026, from $782,810 as of April 30, 2025.
• The company successfully launched a new product line of healthy food products.
• Net cash provided by operating activities was $814,407 in FY2026, a substantial increase from $192,774 in FY2025.

Negatives

• The company reported a net loss of $37,304 in FY2026, compared to a net income of $850,746 in FY2025.
• Gross profit margin declined significantly from 59% in FY2025 to 30% in FY2026.
• General and administrative expenses increased by 364% to $733,795 in FY2026, primarily due to higher legal and professional fees and stock compensation expense.
• Disclosure controls and internal control over financial reporting were deemed not effective due to material weaknesses.

Risks

• Reliance on information technology systems and third-party service providers makes the company vulnerable to cybersecurity threats.
• As a smaller reporting company, limited financial and personnel resources are dedicated to information security.
• The company does not maintain product liability insurance, clinical trial insurance, key person insurance, or business interruption insurance.
• The company's business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns.
• Failure of third-party manufacturers to comply with regulatory requirements could lead to product recalls and damage the company's reputation.
• The company's operations are subject to extensive government regulations, including those from the FDA and FTC, which could impact product marketing and sales.

Future Outlook

The company's upcoming subscription platform is expected to enhance customer retention, increase purchase frequency, and contribute to recurring revenue. Management believes this diversified approach enables effective engagement with both online and offline consumers and supports scalable expansion in the United States and internationally.

Management Comments

• Management views the food trading business primarily as a source of revenue and cash flow to support the company's broader operations.
• Management believes the dual-brand system enables diversified consumer coverage while maintaining a consistent compliance framework and operational efficiencies.
• Management believes the employer-employee relationships in the Company are positive.
• Management intends to grow the employee base in response to the demands and requirements of the business.
• Management intends to remediate material weaknesses in internal controls by evaluating the appointment of additional directors with appropriate financial expertise and engaging or hiring additional qualified accounting personnel.

Industry Context

StockSavvy.ai notes that VitaNova Life Sciences operates in the competitive U.S. nutritional supplements market, which is characterized by fragmentation and low barriers to entry. The company's strategy of a dual-brand approach (GeneCode and AMZ) and an asset-light model, outsourcing manufacturing and fulfillment, is a common tactic to manage costs and scale in this industry. The expansion into healthy food products aligns with broader consumer trends towards wellness and healthy eating.

Comparison to Industry Standards

• The company's gross profit margin of 30% in FY2026 is significantly lower than the typical margins seen in the higher-margin segment of the dietary supplement industry, which can range from 50% to 70% for established brands with strong market presence.
• The substantial increase in general and administrative expenses (364%) in FY2026, particularly legal and professional fees, suggests potential challenges in navigating regulatory compliance or addressing operational complexities, which is a common concern for smaller companies in the highly regulated health and wellness sector.
• The company's reliance on third-party contract manufacturers and logistics partners is a standard practice in the industry to maintain an asset-light model, but it also introduces supply chain risks and quality control challenges that need to be managed diligently.

Corporate Governance

Related Party Transactions

• The company received free office space from a stockholder.
• A stockholder and director advanced funds to the company for working capital purposes; these advances were unsecured, non-interest bearing, and due on demand.
• Compensation arrangements with directors and executive officers are disclosed in the Executive Compensation section.

Stakeholder Impact

• Shareholders may be impacted by the net loss in FY2026 and the decline in gross profit margin, potentially affecting stock valuation.
• Employees may be affected by the company's stated intention to grow its employee base and the ongoing efforts to improve internal controls.
• Suppliers may be impacted by the company's reliance on specific vendors, as Vendor A accounted for 41% of purchases in FY2026.

Next Steps

• Management intends to remediate material weaknesses in internal controls by evaluating the appointment of additional directors with appropriate financial expertise and engaging or hiring additional qualified accounting personnel.
• The company plans to grow its employee base in response to business demands.
• The company is evaluating the impact of recently issued accounting pronouncements.

Key Dates

Recommendation

While revenue growth is positive, the significant shift to a net loss, reduced gross margins, and increased operating expenses are concerning. The identified material weaknesses in internal controls also warrant caution. However, the strong cash position and the potential of the new food product line suggest a 'hold' recommendation pending evidence of improved profitability and remediation of control deficiencies.

Keywords

VitaNova Life Sciences, Dietary Supplements, Healthy Food Products, NutriPeak Trading Corporation, VitaNova Global Foods Corporation, Consumer Health, B2B, Form 10-K